News

Clinical Leader Spotlight: Empowering Patient Adherence Through the BEAMER Project (DUPLICATE)

Published on: 08/05/2024

Clinical Leader Spotlight: Empowering Patient Adherence Through the BEAMER Project (DUPLICATE)

BEAMER project is working on developing a model that will help promote better adherence behaviour and improve quality care.

Projects

Welcome to the 3rd issue of the BEAMER project newsletter. We have specially designed this newsletter for you to keep you up-to-date with the latest developments!

About the project:

BEAMER BEAMER, which stands for BEhavioral and Adherence Model for improving quality, health outcomes, and cost-Effectiveness of healthcaRe, is a project focused on understanding and enhancing treatment adherence. By leveraging insights from behavioural science, BEAMER aims to develop an open-source model that identifies the key factors influencing treatment adherence. This model will enable the identification of patient subpopulations based on their unique needs, laying the groundwork for tailored solutions to improve adherence behaviour. With collaboration from 27 partners across the healthcare spectrum—including universities, healthcare providers, patient organizations, research and technology firms, nonprofit organizations, and global pharmaceutical companies—This collaborative effort promises to revolutionize adherence support, ensuring that the right patients receive the right support at the right time.

 

ECHAlliance’s role in BEAMER:

ECHAlliance is a partner of the BEAMER project as the Communications and Dissemination Lead. To find out more about the project, visit the website here.

ACKNOWLEDGEMENT & DISCLAIMER: The BEAMER project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101034369. This joint undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme, the European Federation of Pharmaceutical Industries and Associations (EFPIA) and Link2Trials.  This communication reflects the views of the authors and neither the IMI nor the European Union, EFPIA, or Link2Trials are liable for any use that may be made of the information contained herein.

 

NEWS​

Related News

VUGENE secures 1 million Euros to revolutionize biological research

7 May 2025
VUGENE, a Lithuania-based multi-omics data analysis company, has announced the closing an investment round of €1 million, led by Superhero Capital tog...

AMR EDUCare: Empowering europe’s healthcare professionals to tackle antimicrobial resistance

6 May 2025

Connect, Innovate, and Transform Healthcare at the AHB Symposium 2025

6 May 2025

Shaping the Future of Digital Health: Insights from the Foresight 2030 Study

6 May 2025

MedFIT 2025

6 May 2025

Have your say: Open Public Consultation for the BeWell Skills Strategy (DUPLICATE)

6 May 2025

Become a member

Join ECHAlliance to amplify your organisation’s message, grow your networks, connect with innovators and collaborate globally.
 
First name *
Last Name *
Email Address *
Country *
Position *
First name *
Last Name *
Email Address *
Country *
Position *